We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002195:SZSEShanghai Stonehill Technology Co., Ltd. Analysis

Data as of 2026-06-12 - not real-time

CN¥6.88

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Shanghai Stonehill Technology trades around CNY 6.88, just above its computed support of CNY 6.72, while the 20‑day SMA (CNY 7.70) and 50‑day SMA (CNY 8.47) sit higher, indicating limited upside. The RSI is deep in oversold territory (~27) and the MACD histogram is negative, suggesting short‑term buying pressure but a bearish momentum bias. Valuation metrics are starkly misaligned: a trailing P/E of 688 versus an industry average of 36.9, yet a forward P/E of ~18.6 hints at potential earnings recovery. The stock’s beta (≈0.59) points to modest market sensitivity, but 30‑day volatility is high at ~38%, and volume trends are decreasing, raising liquidity concerns.
Fundamentally, the company posts negative operating cash flow, a modest gross margin (~30%), and a negative ROE, while maintaining a negligible dividend (0.03%). Debt levels are low relative to equity, but the high price‑to‑book (≈3.94) and price‑to‑sales (≈60) suggest the market is pricing in uncertain growth prospects, especially given the regulatory environment for Chinese software firms.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Oversold RSI indicating potential bounce
  • Proximity to technical support at CNY 6.72
  • Bearish MACD histogram suggesting limited upside

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Forward P/E around 18.6 implying earnings recovery
  • Continued negative cash flow and weak margins
  • High valuation relative to earnings and peers

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained operating losses and negative ROE
  • Elevated valuation multiples versus fundamentals
  • Regulatory headwinds in China's software sector

Key Metrics & Analysis

Financial Health

Revenue Growth-0.90%
Profit Margin12.55%
P/E Ratio688.0
ROE-0.96%
ROA-1.91%
Debt/Equity0.65
P/B Ratio3.9
Op. Cash FlowCN¥-240845248
Free Cash FlowCN¥-130785384
Industry P/E36.9

Technical Analysis

TrendNeutral
RSI27.5
SupportCN¥6.72
ResistanceCN¥8.98
MA 20CN¥7.70
MA 50CN¥8.47
MA 200CN¥8.39
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

GradeOvervalued
TypeBlend
Dividend Yield3.00%

Risk Assessment

Beta0.59
Volatility37.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.